Morning, Monday, 9th September 2019
Sixty One Whitehall, London SW1A 2ET
THIS EVENT IS CPD CERTIFIED
This timely seminar will consider the next steps for protecting research integrity, and ensuring that UK research is reproducible and properly executed.
This conference will be an opportunity to consider the Universities UK response to its recent consultation on the revised Concordat to Support Research Integrity, following its expected publication. Delegates will assess the way forward for implementation of the updated Concordat, and steps that will be necessary to ensure compliance.
We expect attendees to consider the changes to the Concordat in relation to recommendations of the House of Commons Science and Technology Committee, on:
- strengthening and updating the Concordat in relation to training;
- improving processes for responding to allegations of misconduct; and
- identification of non-compliance by clarifying the requirements and expectations of higher education institutions.
Delegates will also address the impact on research integrity of the growing open data culture in academic publishing, examining ethical issues surrounding the responsible use of open data for secondary analysis. They will consider the impact of open science on improving reproducibility and replication of results, along with other measures such as reviewing research design and providing ongoing training to academics.
Further sessions will also look at the transparency of clinical trials in the UK. This comes following the House of Commons Science and Technology Select Committee’s inquiry on clinical trials which recommended that the Government commit to the requirements set out in the EU Clinical Trials Regulation post-Brexit, and that measures be taken to sanction failed compliance.
Delegates will also discuss UKRI priorities for establishing a new research integrity watchdog, following the recent publication of UKRI’s delivery plan, committing to establish a body to oversee research misconduct investigations. Attendees will address concerns raised by some within the sector that the body could encourage a research culture focused on compliance, rather than positive research behaviours.